| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4451476
Max Phase: Preclinical
Molecular Formula: C20H19ClN4O3
Molecular Weight: 398.85
Molecule Type: Unknown
Associated Items:
Representations
Canonical SMILES: O=C1Cc2cc(NC(=O)C(=O)N3CCN(c4ccc(Cl)cc4)CC3)ccc2N1
Standard InChI: InChI=1S/C20H19ClN4O3/c21-14-1-4-16(5-2-14)24-7-9-25(10-8-24)20(28)19(27)22-15-3-6-17-13(11-15)12-18(26)23-17/h1-6,11H,7-10,12H2,(H,22,27)(H,23,26)
Standard InChI Key: KWGVEBNVVWUMQT-UHFFFAOYSA-N
Associated Targets(non-human)
Grin2b Glutamate [NMDA] receptor subunit epsilon 2 (915 Activities)
Grin2b Glutamate [NMDA] receptor subunit epsilon 2 (68 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Rattus norvegicus (775804 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 398.85 | Molecular Weight (Monoisotopic): 398.1146 | AlogP: 2.12 | #Rotatable Bonds: 2 |
| Polar Surface Area: 81.75 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
| #RO5 Violations: 0 | HBA (Lipinski): 7 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 0 |
| CX Acidic pKa: 11.25 | CX Basic pKa: 2.69 | CX LogP: 2.25 | CX LogD: 2.25 |
| Aromatic Rings: 2 | Heavy Atoms: 28 | QED Weighted: 0.76 | Np Likeness Score: -1.89 |
References
| 1. Anan K, Masui M, Tazawa A, Tomida M, Haga Y, Kume M, Yamamoto S, Shinohara S, Tsuji H, Shimada S, Yagi S, Hasebe N, Kai H.. (2019) Discovery of NR2B-selective antagonists via scaffold hopping and pharmacokinetic profile optimization., 29 (9): [PMID:30833109] [10.1016/j.bmcl.2019.02.017] |
Source
Source(1):